Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharm ; 13(9): 2891-6, 2016 09 06.
Article in English | MEDLINE | ID: mdl-26655747

ABSTRACT

Many long-acting delivery strategies for ocular indications rely on pH- and/or temperature-driven release of the therapeutic agent and degradation of the drug carrier. Yet, these physiological parameters are poorly characterized in ocular animal models. These strategies aim at reducing the frequency of dosing, which is of particular interest for the treatment of chronic disorders affecting the posterior segment of the eye, such as macular degeneration that warrants monthly or every other month intravitreal injections. We used anesthetized white New Zealand rabbits, Yucatan mini pigs, and cynomolgus monkeys to characterize pH and temperature in several vitreous locations and the central aqueous location. We also established post mortem pH changes in the vitreous. Our data showed regional and species differences, which need to be factored into strategies for developing biodegradable long-acting delivery systems.


Subject(s)
Vitreous Body/metabolism , Anesthetics/therapeutic use , Animals , Haplorhini , Hydrogen-Ion Concentration , Intravitreal Injections/methods , Macaca fascicularis , Male , Models, Animal , Rabbits , Swine , Temperature
2.
Hum Gene Ther ; 23(9): 980-91, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22716662

ABSTRACT

RetinoStat(®) is an equine infectious anemia virus-based lentiviral gene therapy vector that expresses the angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the wet form of age-related macular degeneration. We initiated 6-month safety and biodistribution studies in two species; rhesus macaques and Dutch belted rabbits. After subretinal administration of RetinoStat the level of human endostatin and angiostatin proteins in the vitreous of treated rabbit eyes peaked at ∼1 month after dosing and remained elevated for the duration of the study. Regular ocular examinations revealed a mild to moderate transient ocular inflammation that resolved within 1 month of dosing in both species. There were no significant long-term changes in the electroretinograms or intraocular pressure measurements in either rabbits or macaques postdosing compared with the baseline reading in RetinoStat-treated eyes. Histological evaluation did not reveal any structural changes in the eye although there was an infiltration of mononuclear cells in the vitreous, retina, and choroid. No antibodies to any of the RetinoStat vector components or the transgenes could be detected in the serum from either species, and biodistribution analysis demonstrated that the RetinoStat vector was maintained within the ocular compartment. In summary, these studies found RetinoStat to be well tolerated, localized, and capable of persistent expression after subretinal delivery.


Subject(s)
Genetic Therapy/methods , Genetic Vectors , Infectious Anemia Virus, Equine , Macular Degeneration/metabolism , Macular Degeneration/therapy , Vitreous Body/metabolism , Angiostatins/biosynthesis , Angiostatins/genetics , Animals , Endostatins/biosynthesis , Endostatins/genetics , Humans , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/pathology , Macaca mulatta , Macular Degeneration/pathology , Rabbits , Time Factors , Vitreous Body/pathology , Vitreous Body/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...